Hi I'm Chris.....Last week I started a training contract at 20:20 Selection, an established Medical Sales recruitment company. As a virgin to the industry I prepared myself as best I could for what I was about to undertake. I did all my reading around the career area and the company itself and eventually it came down to taking the plunge and accepting a 2 week trial in a very unpredictable time period for a recruitment consultant, the 2 weeks preceding the Christmas break. This is obviously an odd time in the industry as our Clients will be in one of 2 camps, the 1st of which being the “lets get the most out of our budget spend before the end of the year before its taken away from us in January”, and the 2nd being, “I’ve done all I can this year, lets start again in 2012”.
My 1st day was, as expected, the birth by fire. This is how we operate, take in as much as you can and see if you can keep up. This gave me a great insight into the speed, efficiency, and accuracy required from a consultant. If you’re not 1st, you’re last. This ethos opens up possibilities for huge success but at the same time great falls. After all we are competing against several other companies with differing approaches to achieving the same goal, luckily for me I’m working on the basis of quality rather than quantity. But that doesn’t mean quantity doesn’t get it right some times.
The harsh reality of the other side of recruitment fast became apparent. You really have to shine to get noticed in the current climate and the vast array of approaches that candidates use to attain this is eye opening. The role itself is very diverse. Admin is air tight, and has to be. It can be the difference between placing and missing out, a point regularly re-enforced during my training thus far. Combine admin with confident selective telephone manor, excellent knowledge of your clients and candidates, and the foresight to combine the two and you may have what it takes to take on the world of recruitment.
The industry requires you to effectively sit on a knife edge, the whole game is in balance, continually changing as both clients and candidates change their ‘requirements’, which can either push you right to the top or plunge you back to square one. This makes for a very exciting work environment as we are challenged with the task of keeping the balance in our favour right until the very last minute and then if all goes to plan, we can tip the scales and reap the benefit.
The team currently have the task of not only managing business but also managing me. As a fresh starter I am as keen and eager as you’d expect. I want to get my hands dirty and dive straight in but my lack of experience leaves me blind to the consequence. I am effectively stood on top of a diving board blindfold, trusting my team for direction and timing so I land on soft success rather than the hard ground of misconception. Time will tell……
If you have enjoyed Chris's article please follow him on his journey.
You can also visit the 20:20 Selection website http://www.2020selection.co.uk/ where you will find lots of other useful resources if you are planning a career in medical sales
Friday, 27 January 2012
Clinical Commissioning Groups
CLINICAL COMMISSIONING GROUPS
Please note that if you enjoy reading this blog then you can find other similarly informative articles on our website at http://www.2020selection.co.uk/
A Clinical Commissioning Group (CCG) is a group of GPs and other clinicians who have chosen to come together to commission (buy) health services for their local communities. From early 2013, Clinical Commissioning Groups will be responsible for commissioning NHS services for patients in England. All GPs will need to be part of a CCG. They will replace Primary Care Trusts (PCTs). CCGs will be responsible for commissioning hospital services (elective, acute and emergency) and most community health services (for example district nurses), and mental health services. The 151 PCTs have already been organised into 51 clusters in preparation for the change. There will be a period of dual functioning as CCGs mature and PCTs delegate more responsibility to CCGs.
The governing bodies (Boards) of the CCGs will have, in addition to GPs, a least one registered nurse and a doctor who is a secondary care specialist. Groups will have boundaries that will not normally cross those of local authorities.
Some CCGs have been given authority by central government to test new models of clinical commissioning and to lead in their development – the term ‘pathfinder’ is used to describe such groups.
Commissioning is the term used in the public sector for buying services. It is a structured way of deciding how public money should be spent. In the case of the NHS, commissioning relates to the provision of health services. Commissioning healthcare and health services is the process of examining:
the healthcare needs of the area
the way in which healthcare services are delivered
ways in which healthcare resources will offer the best overall value for money
Health services, such as GPs and community and hospital services have historically been commissioned by PCTs. This way of buying in services has meant that GPs and other clinicians, who are the best placed to advise on their patients needs, have been too far removed from the process.
The health White Paper: Equity & Excellence: Liberating the NHS was published in July 2010. The White Paper reinforces this view, and in time, much of the responsibility for commissioning health services will be given over to clinicians including GPs.
The CCGs will be overseen by the newly formed independent NHS Commissioning Board which will make sure that CCGs have the capacity and capability to commission services successfully and to meet their financial responsibilities. The NHS Commissioning Board will become fully operational from April 2012. Its senior structures should contain a range of healthcare professionals, and it will have a Medical Director and a Chief Nursing Officer on its board.
The NHS Commissioning Board will also be responsible for directly commissioning:
Pharmacy services
General Practice
Dentistry services
Specialist services (specialised services that are required by a limited number of people)
At a local level, new Health and Wellbeing Boards will be set up in local authorities to ensure that CCGs are meeting the needs of local people. The membership of these boards will include representatives from:
Clinical Commissioning Groups
Directors of public health
Children’s services
Adult Social Services
Elected councillors
Health watch (representing the views of patients, carers and local communities)
These boards will be in place in shadow form April 2012.
For further information
More information on the health White Paper: Equity & Excellence:
Liberating the NHS see the Department of Health website:
http://www.dh.gov.uk/en/Healthcare/LiberatingtheNHS/index.htm
Please note that if you enjoy reading this blog then you can find other similarly informative articles on our website at http://www.2020selection.co.uk/
A Clinical Commissioning Group (CCG) is a group of GPs and other clinicians who have chosen to come together to commission (buy) health services for their local communities. From early 2013, Clinical Commissioning Groups will be responsible for commissioning NHS services for patients in England. All GPs will need to be part of a CCG. They will replace Primary Care Trusts (PCTs). CCGs will be responsible for commissioning hospital services (elective, acute and emergency) and most community health services (for example district nurses), and mental health services. The 151 PCTs have already been organised into 51 clusters in preparation for the change. There will be a period of dual functioning as CCGs mature and PCTs delegate more responsibility to CCGs.
The governing bodies (Boards) of the CCGs will have, in addition to GPs, a least one registered nurse and a doctor who is a secondary care specialist. Groups will have boundaries that will not normally cross those of local authorities.
Some CCGs have been given authority by central government to test new models of clinical commissioning and to lead in their development – the term ‘pathfinder’ is used to describe such groups.
Commissioning is the term used in the public sector for buying services. It is a structured way of deciding how public money should be spent. In the case of the NHS, commissioning relates to the provision of health services. Commissioning healthcare and health services is the process of examining:
the healthcare needs of the area
the way in which healthcare services are delivered
ways in which healthcare resources will offer the best overall value for money
Health services, such as GPs and community and hospital services have historically been commissioned by PCTs. This way of buying in services has meant that GPs and other clinicians, who are the best placed to advise on their patients needs, have been too far removed from the process.
The health White Paper: Equity & Excellence: Liberating the NHS was published in July 2010. The White Paper reinforces this view, and in time, much of the responsibility for commissioning health services will be given over to clinicians including GPs.
The CCGs will be overseen by the newly formed independent NHS Commissioning Board which will make sure that CCGs have the capacity and capability to commission services successfully and to meet their financial responsibilities. The NHS Commissioning Board will become fully operational from April 2012. Its senior structures should contain a range of healthcare professionals, and it will have a Medical Director and a Chief Nursing Officer on its board.
The NHS Commissioning Board will also be responsible for directly commissioning:
Pharmacy services
General Practice
Dentistry services
Specialist services (specialised services that are required by a limited number of people)
At a local level, new Health and Wellbeing Boards will be set up in local authorities to ensure that CCGs are meeting the needs of local people. The membership of these boards will include representatives from:
Clinical Commissioning Groups
Directors of public health
Children’s services
Adult Social Services
Elected councillors
Health watch (representing the views of patients, carers and local communities)
These boards will be in place in shadow form April 2012.
For further information
More information on the health White Paper: Equity & Excellence:
Liberating the NHS see the Department of Health website:
http://www.dh.gov.uk/en/Healthcare/LiberatingtheNHS/index.htm
Which Medical Sales Recruitment Agency?
Which Recruitment Agency?
Despite the global recession and credit crunch, one of the UK’s leading pharmaceutical recruitment agencies , 20:20 Selection Ltd has gone from strength to strength. How have they acheived their organic growth in these difficult times?
The team have over 50 years of combined, actual experience in the pharmaceutical and healthcare sales arenas in the UK.
Managing Director Karen Forshaw formed the company in 2002, after a successful career in medical sales (both primary and secondary care) and medical sales management (at both area and national sales manager level). She is passionate about providing an unirivaled service to both clients and candidates. The 20:20 Selection maxim of “perfect vision: not hindsight” extols the company virtues down to a tee. By carefully selecting their candidates, 20:20 Selection ensure that when one goes before a client for an interview then they have an excellent chance of actually getting hired.
Using the experience and advice from Karen’s team, 20:20 Selection will ensure that you are only ever put forward for roles which you really understand and want to do. They only send your CV to clients with your full permission. Should you get an interview, then Karen and the team will keep you fully briefed and ‘prepped’ during the entire process. They have an enviable reputation within the industry as a recruitment company that really cares about both clients and candidates. One of the prime motivating factors is that individual consultants are not bonussed on just their own performance, but on the performance of the whole company. As a result you will not find yourself being forced or coerced into going for a role just to make up the sales figures of the consultant that you are dealing with.
So if you are interested in a role in UK pharmaceutical, medical or device sales then please contact us at administrator@2020selection.co.uk or visit our website http://www.2020selection.co.uk/ to find out more about the company.
Please note that in order to reach our minimum standards you will need to be qualified to work in the UK, have a full UK driving licence with not more than 6 points and be educated to degree level or be of graduate calibre.
Good Luck in your career.
Despite the global recession and credit crunch, one of the UK’s leading pharmaceutical recruitment agencies , 20:20 Selection Ltd has gone from strength to strength. How have they acheived their organic growth in these difficult times?
The team have over 50 years of combined, actual experience in the pharmaceutical and healthcare sales arenas in the UK.
Managing Director Karen Forshaw formed the company in 2002, after a successful career in medical sales (both primary and secondary care) and medical sales management (at both area and national sales manager level). She is passionate about providing an unirivaled service to both clients and candidates. The 20:20 Selection maxim of “perfect vision: not hindsight” extols the company virtues down to a tee. By carefully selecting their candidates, 20:20 Selection ensure that when one goes before a client for an interview then they have an excellent chance of actually getting hired.
Using the experience and advice from Karen’s team, 20:20 Selection will ensure that you are only ever put forward for roles which you really understand and want to do. They only send your CV to clients with your full permission. Should you get an interview, then Karen and the team will keep you fully briefed and ‘prepped’ during the entire process. They have an enviable reputation within the industry as a recruitment company that really cares about both clients and candidates. One of the prime motivating factors is that individual consultants are not bonussed on just their own performance, but on the performance of the whole company. As a result you will not find yourself being forced or coerced into going for a role just to make up the sales figures of the consultant that you are dealing with.
So if you are interested in a role in UK pharmaceutical, medical or device sales then please contact us at administrator@2020selection.co.uk or visit our website http://www.2020selection.co.uk/ to find out more about the company.
Please note that in order to reach our minimum standards you will need to be qualified to work in the UK, have a full UK driving licence with not more than 6 points and be educated to degree level or be of graduate calibre.
Good Luck in your career.
Friday, 6 January 2012
High Tech drugs dominate NHS England drug expenditure
When the NHS was launched in 1948 it had a budget of £437million (roughly £9billion at today’s value). For 2011/12 it is around £106 billion. This equates to an average rise in spending over the full 60-year period of about 4% a year once inflation has been taken into account. However, in recent years investment levels have been double that to fund a major modernisation programme.
Some 60% of the NHS budget is used to pay staff. A further 20% pays for drugs and other supplies, with the remaining 20% split between buildings, equipment and training costs on the one hand and medical equipment, catering and cleaning on the other. Nearly 80% of the total budget is distributed by local trusts in line with the particular health priorities in their areas.
The money to pay for the NHS comes directly from taxation. According to independent bodies such as the King’s Fund, this remains the “cheapest and fairest” way of funding health care when compared with other systems.
Overall, drug expenditure represents about 10% of NHS drug expenditure. Following the 2010 General Election, the coalition government agreed that all NICE approved drugs should be made readily available to all NHS England patients, irrespective of where they live, and as a direct consequence there has been a steady increase in the value of drugs issued in hospitals (secondary care). This equates closely with the fact that the newer drugs positively appraised by NICE tend to be very expensive in terms of acquisition cost (i.e. trade price to the NHS).
The overall NHS expenditure on medicines in 2009 was £12.3 billion.
The overall NHS expenditure on medicines in 2010 was £12.9 billion.
In 2009 hospital use accounted for 30.9% of the total cost, up from 28.8% in 2008.
In 2010 hospital use accounted for 31.7 per cent of the total cost, up from 30.9 percent in 2009.
In 2009, the cost of medicines rose by 4.8 per cent overall but by 7.7 per cent in hospitals
In 2010, the cost of medicines rose by 5.6% overall but by 13.2% in hospitals
In 2009, of the drugs positively appraised by NICE, the greatest overall cost was for atorvastatin but etanercept incurred the greatest cost in hospitals.
In 2010, of the drugs positively appraised by NICE, the greatest overall cost was for atorvastatin but adalimumab incurred the greatest cost in hospitals.
Table 1. Cost (£000s) of top 10 medicines issued in hospital in 2010
1. Adalimumab (Humira) 180,519.7
2. Etanercept (Enbrel) 179,631.0
3. Ranibizumab (Lucentis) 128,984.7
4. Trastuzumab (Herceptin) 105,878.0
5. Infliximab (Remicade) 103,437.6
6. Rituximab (Rituxan/MabThera) 93,672.3
7. Imatinib (Glivec) 55,262.9
8. Docetaxel (Taxotere) 52,994.3
9. Lenalidomide (Revlimid) 49,676.9
10.Oxaliplatin (Eloxatin) 44,087.5
Table 2. Cost (£000s) of top 10 medicines issued in Primary care in 2010
1. Atorvastatin (Lipitor) 305,652.7
2. Olanzapine (Zyprexa) 110,045.1
3. Quetiapine (Seroquel) 88,915.7
4. Omeprazole (generic) 84,252.0
5. Simvastatin (including combinations) mainly generic 82,134.8
6. Ezetimibe (excluding combinations) Ezetrol family 77,454.3
7. Insulin glargine (Lantus) 73,723.7
8. Pioglitazone (inc with metformin) Actos family 68,132.9
9. Buprenorphine (inc with naloxone) Subutex family 57,646.7
10.Levitiracetam (Keppra) 54,350.8
Table 3. Overall cost (£000s) of top 10 medicines issued in ALL sectors 2010
1. Atorvastatin (Lipitor) 312,871.9
2. Adalimumab (Humira) 189,302.7
3. Etanercept (Enbrel) 188,628.2
4. Ranibizumab (Lucentis) 128,987.0
5. Olanzapine (Zyprexa) 126,501.6
6. Trastuzumab (Herceptin) 105,878.0
7. Infliximab (Remicade) 103,439.7
8. Quetiapine (Seroquel) 101,992.3
9. Rituximab (Rituxan/MabThera) 93,673.4
10.Omeprazole (generic) 91,313.7
Table 4. Cost (£000s) of top 10 medicines issued in hospital in 2009
1. Etanercept (Enbrel) 158,377.8
2. Adalimumab (Humira) 150,592.6
3. Trastuzumab (Herceptin) 96,126.0
4. Ranibizumab (Lucentis) 94,694.8
5. Infliximab (Remicade) 90,387.3
6. Rituximab (Rituxan/MabThera) 79,391.7
7. Imatinib (Glivec) 54,105.2
8. Docetaxel (Taxotere) 49,711.0
9. Oxaliplatin (Eloxatin) 39,913.9
10.Paclitaxel (Taxol) 34,822.1
Table 5. Cost (£000s) of top 10 medicines issued in Primary care in 2009
1. Atorvastatin (Lipitor) 321,499.6
2. Clopidogrel (Plavix) 136,574.7
3. Olanzapine (Zyprexa) 106,073.6
4. Quetiapine (Seroquel) 78,682.9
5. Simvastatin (including combinations) mainly generic 73,470.9
6. Ezetimibe (excluding combinations) Ezetrol family 71,409.0
7. Insulin glargine (Lantus) 66,753.3
8. Simvastatin (excluding combinations) generic 66,753.3
9. Omeprazole (generic) 65,796.8
10.Rosuvastatin (Crestor) 51,662.8
Table 6. Overall cost (£000s) of top 10 medicines issued in ALL sectors 2009
1. Atorvastatin (Lipitor) 328,652.1
2. Etanercept (Enbrel) 166,450.4
3. Adalimumab (Humira) 157,022.6
4. Clopidogrel (Plavix) 149,455.2
5. Olanzapine (Zyprexa) 123,113.1
6. Trastuzumab (Herceptin) 96,126.0
7. Ranibizumab (Lucentis) 94,695.5
8. Quetiapine (Seroquel) 91,805.0
9. Infliximab (Remicade) 90,387.3
10.Rituximab (Rituxan/MabThera) 79,392.0
Interestingly, the UK patents for the following brands will/have expire(d) in the following years. Clearly this will have a major impact on future data released in 2012.
Lipitor (2012)
Plavix (2010)
Zyprexa (2011)
Seroquel (tbc)
Due to the complex nature of patent law these dates are best estimates, at the time of writing this article and can not therefore be guaranteed.
Sources:
The NHS Information Centre http://www.ic.nhs.uk/
If you find this article useful, please visit http://www.2020selection.co.uk to find more articles that you may be interested in. Please look in the ‘Candidate’ section.
Some 60% of the NHS budget is used to pay staff. A further 20% pays for drugs and other supplies, with the remaining 20% split between buildings, equipment and training costs on the one hand and medical equipment, catering and cleaning on the other. Nearly 80% of the total budget is distributed by local trusts in line with the particular health priorities in their areas.
The money to pay for the NHS comes directly from taxation. According to independent bodies such as the King’s Fund, this remains the “cheapest and fairest” way of funding health care when compared with other systems.
Overall, drug expenditure represents about 10% of NHS drug expenditure. Following the 2010 General Election, the coalition government agreed that all NICE approved drugs should be made readily available to all NHS England patients, irrespective of where they live, and as a direct consequence there has been a steady increase in the value of drugs issued in hospitals (secondary care). This equates closely with the fact that the newer drugs positively appraised by NICE tend to be very expensive in terms of acquisition cost (i.e. trade price to the NHS).
The overall NHS expenditure on medicines in 2009 was £12.3 billion.
The overall NHS expenditure on medicines in 2010 was £12.9 billion.
In 2009 hospital use accounted for 30.9% of the total cost, up from 28.8% in 2008.
In 2010 hospital use accounted for 31.7 per cent of the total cost, up from 30.9 percent in 2009.
In 2009, the cost of medicines rose by 4.8 per cent overall but by 7.7 per cent in hospitals
In 2010, the cost of medicines rose by 5.6% overall but by 13.2% in hospitals
In 2009, of the drugs positively appraised by NICE, the greatest overall cost was for atorvastatin but etanercept incurred the greatest cost in hospitals.
In 2010, of the drugs positively appraised by NICE, the greatest overall cost was for atorvastatin but adalimumab incurred the greatest cost in hospitals.
Table 1. Cost (£000s) of top 10 medicines issued in hospital in 2010
1. Adalimumab (Humira) 180,519.7
2. Etanercept (Enbrel) 179,631.0
3. Ranibizumab (Lucentis) 128,984.7
4. Trastuzumab (Herceptin) 105,878.0
5. Infliximab (Remicade) 103,437.6
6. Rituximab (Rituxan/MabThera) 93,672.3
7. Imatinib (Glivec) 55,262.9
8. Docetaxel (Taxotere) 52,994.3
9. Lenalidomide (Revlimid) 49,676.9
10.Oxaliplatin (Eloxatin) 44,087.5
Table 2. Cost (£000s) of top 10 medicines issued in Primary care in 2010
1. Atorvastatin (Lipitor) 305,652.7
2. Olanzapine (Zyprexa) 110,045.1
3. Quetiapine (Seroquel) 88,915.7
4. Omeprazole (generic) 84,252.0
5. Simvastatin (including combinations) mainly generic 82,134.8
6. Ezetimibe (excluding combinations) Ezetrol family 77,454.3
7. Insulin glargine (Lantus) 73,723.7
8. Pioglitazone (inc with metformin) Actos family 68,132.9
9. Buprenorphine (inc with naloxone) Subutex family 57,646.7
10.Levitiracetam (Keppra) 54,350.8
Table 3. Overall cost (£000s) of top 10 medicines issued in ALL sectors 2010
1. Atorvastatin (Lipitor) 312,871.9
2. Adalimumab (Humira) 189,302.7
3. Etanercept (Enbrel) 188,628.2
4. Ranibizumab (Lucentis) 128,987.0
5. Olanzapine (Zyprexa) 126,501.6
6. Trastuzumab (Herceptin) 105,878.0
7. Infliximab (Remicade) 103,439.7
8. Quetiapine (Seroquel) 101,992.3
9. Rituximab (Rituxan/MabThera) 93,673.4
10.Omeprazole (generic) 91,313.7
Table 4. Cost (£000s) of top 10 medicines issued in hospital in 2009
1. Etanercept (Enbrel) 158,377.8
2. Adalimumab (Humira) 150,592.6
3. Trastuzumab (Herceptin) 96,126.0
4. Ranibizumab (Lucentis) 94,694.8
5. Infliximab (Remicade) 90,387.3
6. Rituximab (Rituxan/MabThera) 79,391.7
7. Imatinib (Glivec) 54,105.2
8. Docetaxel (Taxotere) 49,711.0
9. Oxaliplatin (Eloxatin) 39,913.9
10.Paclitaxel (Taxol) 34,822.1
Table 5. Cost (£000s) of top 10 medicines issued in Primary care in 2009
1. Atorvastatin (Lipitor) 321,499.6
2. Clopidogrel (Plavix) 136,574.7
3. Olanzapine (Zyprexa) 106,073.6
4. Quetiapine (Seroquel) 78,682.9
5. Simvastatin (including combinations) mainly generic 73,470.9
6. Ezetimibe (excluding combinations) Ezetrol family 71,409.0
7. Insulin glargine (Lantus) 66,753.3
8. Simvastatin (excluding combinations) generic 66,753.3
9. Omeprazole (generic) 65,796.8
10.Rosuvastatin (Crestor) 51,662.8
Table 6. Overall cost (£000s) of top 10 medicines issued in ALL sectors 2009
1. Atorvastatin (Lipitor) 328,652.1
2. Etanercept (Enbrel) 166,450.4
3. Adalimumab (Humira) 157,022.6
4. Clopidogrel (Plavix) 149,455.2
5. Olanzapine (Zyprexa) 123,113.1
6. Trastuzumab (Herceptin) 96,126.0
7. Ranibizumab (Lucentis) 94,695.5
8. Quetiapine (Seroquel) 91,805.0
9. Infliximab (Remicade) 90,387.3
10.Rituximab (Rituxan/MabThera) 79,392.0
Interestingly, the UK patents for the following brands will/have expire(d) in the following years. Clearly this will have a major impact on future data released in 2012.
Lipitor (2012)
Plavix (2010)
Zyprexa (2011)
Seroquel (tbc)
Due to the complex nature of patent law these dates are best estimates, at the time of writing this article and can not therefore be guaranteed.
Sources:
The NHS Information Centre http://www.ic.nhs.uk/
If you find this article useful, please visit http://www.2020selection.co.uk to find more articles that you may be interested in. Please look in the ‘Candidate’ section.
Tuesday, 24 August 2010
20:20 Selection Ltd – Crucell Team expansion
In 2009, Crucell – the largest independent vaccines company in the world – launched a dedicated Sales & Marketing function in the
The expansion of the sales team is a reflection of the successful first year of the UK Sales & Marketing function, and represents an excellent time to join the team as they capitalise on their achievements to date. Crucell firmly believe that investing in their people is investing in the future, and is dedicated to developing employees’ competencies and promoting individual performance.
Brand new opportunities now exist for Territory and Regional Business Managers to join the company throughout
On offer to successful candidates will be a highly attractive basic salary, company car or car allowance, excellent bonus potential, 25 days holiday, pension & private healthcare. Crucell UK Ltd is a growing organisation with
full investment from their headquarters in
Thursday, 5 August 2010
Health White Paper - Lansley's Health Reforms
The new Health Minister announced the White Paper that lays out the future of the NHS over the course of this parliament (which is now a guaranteed 5 years). He described this as a ‘blueprint’ for Health Policy up to the next General Election. The main aim is to cut £20bn from the Health Budget over the next 4 years. One of the main issues is the end of the current PCTs, which means that GPs will have direct control of the commissioning of services. NHS Management costs are set to reduce by 45% as a part of this reduction.
This is considered by many to be the most radical NHS White Paper to date, and is expected to be well received by the Conservative back benches. As for the Lib Dems, they had the abolition of StHAs as part of their 2010 manifesto, so this should sit well with them also.
Lansley said ‘the provision of healthcare service will be led by patients and professionals and not by politicians’.
The basics of the White Paper are set out below:
More power to GPs
The most contentious issues will be the compulsory devolvement of huge commissioning powers to GP and GP Consortia and the abolition of Primary Care Trusts (PCTs). None of this was proposed by the Conservatives when they were in opposition. These decisions emerged after the General Election. There is concern that a large number of GPs do not want to take on commissioning functions, and in fact are ill-equipped to do so.
It is interesting therefore to note that the British Medical Association has welcomed today’s announcement.
More power to patients
The Government is going to launch HealthWatch England, a new ‘consumer champion’, which will sit within the Care Quality Commission (CQC). The White Paper provides an ethos for structural change; the NHS must be patient led and choices must be led by those at the frontline of delivering those services to patients, i.e. clinicians. On a national level, it will be able to propose CQC investigations of poor service. This organisation will help to strengthen the patient voice and ensure that patient feedback is heard at a local level. Patients will not only have power over the choice of GP they would like to attend (regardless of where they live), but will also have power over who has sight of their patient record.
Abolition of Primary Care Trusts (PCTs)
The complete removal of PCTs, instead of simply reducing their numbers, came as a big surprise when compared to the proposals contained in the Conservative manifesto from January 2010. However, it is in keeping with current measures when you look at the plan to reduce admin costs by 45%. Some form of supervisory role is of course required, particularly in respect of GPs and other primary care services, and it is a role which Monitor (the body currently responsible for the regulation of Foundation Trusts) may find challenging.
Abolition of Strategic Health Authorities (SHAs)
SHAs will be abolished as early as 2012. Their functions will be taken over by Monitor. Monitors’ remit will extend to establish it as the key economic regulator in healthcare.
Foundation Trusts
All NHS Trusts will become or be part of a Foundation Trust and this will be the preferred governance model for the health service. Trusts will be given more freedom to innovate to improve patient care. NHS staff will have the opportunity - where appropriate – to manage these organisations as ‘the largest social enterprise sector in the world’.
NHS Commissioning Board
A review of existing quangos is due to report in the autumn but the White Paper makes provision for a number of new bodies which will help implement this new, patient led vision of the NHS. The most vital is the NHS Commissioning Board which will act to ensure quality in commissioning and be responsible for commissioning certain services, such as community pharmacy, which GPs cannot commission. It will also be responsible for increasing patient choice through helping patients manage their personal health budgets. The intention is for this body to be fully operational in April 2012. The underpinning concept is to reduce the number of quangos but those that do exist will be interlinked and more accessible to patients.
Value based pricing
The White Paper confirms that the Government intends to move to value based pricing when the current Pharmaceutical Price Regulation Scheme (PPRS) runs out at the end of 2013. A reference is made to the Cancer Drugs Fund, which will operate from April 2011, but no further details are provided.
NICE
In a further strengthening of its powers, NICE will be in charge of developing new quality standards for all the main pathways of care. The paper estimates that NICE will develop up to 150 new quality standards over the next five years. This will position NICE as the key quality regulator building on Lord Darzi’s work on quality improvements, under the previous Government.
Scrapping targets
As mentioned in the NHS Operating Framework, targets with ‘no clinical justification’ will be scrapped (although not as many as were discussed in Opposition). There is a concession that some targets do work but the paper is not clear on which ones and a consultation is promised on new measureables.
Long Term Care
A Commission will be set up to look into long-term care from the Department of Health. This is in keeping with the move to strip away the Department’s NHS functions and replace them with longer term social care objectives.
Consultation
A number of consultation papers will be published in the near future, getting stakeholder views on policies including; commissioning for patients, freeing providers and economic regulation, the NHS outcomes framework, the framework for transition. This process will be an important part of the transition to the new system as will the proper management of the financial risk.
Legislation
Primary legislation will be required to make many of the proposed changes in the White Paper. The Health Bill announced in the Queen’s Speech provides for many of these reforms and is due to be introduced in late 2010. The main legislative reforms in the Bill will include: Making improvement in outcomes central to the NHS; Reforming NICE; creating the independent NHS Commissioning Board; creating a framework for a comprehensive system of GP consortia; establishing HealthWatch; reforming the Foundation Trust model; developing Monitor’s role and reducing the number of arms length bodies in health. The Department of Health is taking comments on implementing all the changes in the Health Bill, which must be submitted by 5 October 2010. We can therefore deduce that the Health Bill will not be laid before Parliament before this date.
The Health Bill will also support the creation of a new Public Health Service, which will streamline existing health improvement and protection bodies. Another White Paper, this time on public health will be published later this year. In addition, the public health budget will be ring-fenced and local Directors of Public Health will be responsible for health improvement funds allocated according to local need.
Sources: white paper and Mr Lansleys press release.
This is considered by many to be the most radical NHS White Paper to date, and is expected to be well received by the Conservative back benches. As for the Lib Dems, they had the abolition of StHAs as part of their 2010 manifesto, so this should sit well with them also.
Lansley said ‘the provision of healthcare service will be led by patients and professionals and not by politicians’.
The basics of the White Paper are set out below:
More power to GPs
The most contentious issues will be the compulsory devolvement of huge commissioning powers to GP and GP Consortia and the abolition of Primary Care Trusts (PCTs). None of this was proposed by the Conservatives when they were in opposition. These decisions emerged after the General Election. There is concern that a large number of GPs do not want to take on commissioning functions, and in fact are ill-equipped to do so.
It is interesting therefore to note that the British Medical Association has welcomed today’s announcement.
More power to patients
The Government is going to launch HealthWatch England, a new ‘consumer champion’, which will sit within the Care Quality Commission (CQC). The White Paper provides an ethos for structural change; the NHS must be patient led and choices must be led by those at the frontline of delivering those services to patients, i.e. clinicians. On a national level, it will be able to propose CQC investigations of poor service. This organisation will help to strengthen the patient voice and ensure that patient feedback is heard at a local level. Patients will not only have power over the choice of GP they would like to attend (regardless of where they live), but will also have power over who has sight of their patient record.
Abolition of Primary Care Trusts (PCTs)
The complete removal of PCTs, instead of simply reducing their numbers, came as a big surprise when compared to the proposals contained in the Conservative manifesto from January 2010. However, it is in keeping with current measures when you look at the plan to reduce admin costs by 45%. Some form of supervisory role is of course required, particularly in respect of GPs and other primary care services, and it is a role which Monitor (the body currently responsible for the regulation of Foundation Trusts) may find challenging.
Abolition of Strategic Health Authorities (SHAs)
SHAs will be abolished as early as 2012. Their functions will be taken over by Monitor. Monitors’ remit will extend to establish it as the key economic regulator in healthcare.
Foundation Trusts
All NHS Trusts will become or be part of a Foundation Trust and this will be the preferred governance model for the health service. Trusts will be given more freedom to innovate to improve patient care. NHS staff will have the opportunity - where appropriate – to manage these organisations as ‘the largest social enterprise sector in the world’.
NHS Commissioning Board
A review of existing quangos is due to report in the autumn but the White Paper makes provision for a number of new bodies which will help implement this new, patient led vision of the NHS. The most vital is the NHS Commissioning Board which will act to ensure quality in commissioning and be responsible for commissioning certain services, such as community pharmacy, which GPs cannot commission. It will also be responsible for increasing patient choice through helping patients manage their personal health budgets. The intention is for this body to be fully operational in April 2012. The underpinning concept is to reduce the number of quangos but those that do exist will be interlinked and more accessible to patients.
Value based pricing
The White Paper confirms that the Government intends to move to value based pricing when the current Pharmaceutical Price Regulation Scheme (PPRS) runs out at the end of 2013. A reference is made to the Cancer Drugs Fund, which will operate from April 2011, but no further details are provided.
NICE
In a further strengthening of its powers, NICE will be in charge of developing new quality standards for all the main pathways of care. The paper estimates that NICE will develop up to 150 new quality standards over the next five years. This will position NICE as the key quality regulator building on Lord Darzi’s work on quality improvements, under the previous Government.
Scrapping targets
As mentioned in the NHS Operating Framework, targets with ‘no clinical justification’ will be scrapped (although not as many as were discussed in Opposition). There is a concession that some targets do work but the paper is not clear on which ones and a consultation is promised on new measureables.
Long Term Care
A Commission will be set up to look into long-term care from the Department of Health. This is in keeping with the move to strip away the Department’s NHS functions and replace them with longer term social care objectives.
Consultation
A number of consultation papers will be published in the near future, getting stakeholder views on policies including; commissioning for patients, freeing providers and economic regulation, the NHS outcomes framework, the framework for transition. This process will be an important part of the transition to the new system as will the proper management of the financial risk.
Legislation
Primary legislation will be required to make many of the proposed changes in the White Paper. The Health Bill announced in the Queen’s Speech provides for many of these reforms and is due to be introduced in late 2010. The main legislative reforms in the Bill will include: Making improvement in outcomes central to the NHS; Reforming NICE; creating the independent NHS Commissioning Board; creating a framework for a comprehensive system of GP consortia; establishing HealthWatch; reforming the Foundation Trust model; developing Monitor’s role and reducing the number of arms length bodies in health. The Department of Health is taking comments on implementing all the changes in the Health Bill, which must be submitted by 5 October 2010. We can therefore deduce that the Health Bill will not be laid before Parliament before this date.
The Health Bill will also support the creation of a new Public Health Service, which will streamline existing health improvement and protection bodies. Another White Paper, this time on public health will be published later this year. In addition, the public health budget will be ring-fenced and local Directors of Public Health will be responsible for health improvement funds allocated according to local need.
Sources: white paper and Mr Lansleys press release.
Friday, 7 May 2010
Securing your next role – What NOT to do!
Landing a job is never easy, as the industry is now in a state of flux it is more competitive these days. There are fewer vacancies and more people chasing them than in more than a decade. But even now -- more than ever -- it's still on you. Despite the fact that the job market is everything but easy right now... have you ever stopped to consider that the reason you're still sitting there unemployed ... might in fact be ... you?
It's a hard concept that most job seekers have trouble wrapping their heads around, but applicants frequently -- inadvertently -- raise red flags to recruiting managers that immediately scream, "Don't employ me!" You might not be raising them on purpose, but there are ways to avoid them.
Not sure if you're unknowingly blowing your chances at securing your dream position? Here are 10 red flags to be wary of during your next job hunt:
Red flag No. 1: Your CV is lacking any specific achievements that distinguish you from other Medical Representatives
When you're crafting your CV, you should focus on highlighting relevant skills and accomplishments that are in line with the position for which you are applying. Highlighting your sales successes is key!
Red flag No. 2: You have long gaps between jobs on your CV
Even if your long departure from the work force is valid, extended lapses of unemployment might say to an employer, "Why weren't you wanted by anyone?" Anytime you have more than a three-month gap of idleness on your CV, legitimate or otherwise, be prepared to explain yourself.
Red flag No. 3: You aren't prepared for the interview
There are many ways to be unprepared for an interview: You haven't researched the company, you haven’t researched the products & therapy area, you don't have any questions prepared, etc. Plain and simple, do your homework before an interview. Explore the company online, prepare answers to Competency Based questions and have someone give you a mock interview. The more prepared you are, the more employers will take you seriously.
Red flag No. 4: You didn't provide any evidence of success
In today’s competitive market use of evidence/brag file can be the difference between progressing to the next stage and being told that there ‘where stronger people on the day.’ You need to prove how successful you have been (the more specific you can be the better) and differentiate yourself from other candidates. Do not wait to be asked for your evidence, use it as a sales aid to illustrate your answers. YOU are your product!
Red flag No. 5: You only have negative things to say about previous employment
If you feel aggrieved or down-beat about your current/prior employer, it could be very tempting to want to tell anyone who will listen how much of ‘bad time’ you have experienced-- but a recruiting manager for a coveted job is not that person. There are hundreds of ways to turn negative things about an old job into positives. Thought your last job was a dead end? Spin it by saying, "I felt I had gone as far as I could go in that position. I'm looking for something with more opportunity for advancement."
Red flag No. 6: You've held seven different jobs -- in the past six years
Job hopping is a new trend in the working world. Workers are no longer staying in a job for 10-20 years; they stay for a couple and move on to the next one. While such a tactic can further your career, switching jobs too often will raise a prospective employer's antenna. Too many jobs in too little time tells employers that either you can't hold a job or you have no loyalty. Be prepared to explain your reasoning/rationale
Red flag No. 7: You give inconsistent answers in your interview
One tactic recruiting manager’s use during the recruitment process is to ask you the same question in several different ways. This is mostly to ensure that you're genuine with your answers and not just telling an employer what he or she wants to hear. Keep your responses sincere throughout the entire process and you should be good to go.
Red flag No. 8: You lack flexibility
Most people know what they want in a job as far as benefits, basic salary, bonus, etc. If you're unable to be flexible with some of your (unrealistic?) expectations, however, you're going to have a difficult time finding a job. Have a bottom line in terms of what you want before you start the job hunting process and be willing to bend a bit if necessary.
Red flag No. 9: Your application was -- in a word – lazy
Only doing the bare minimum of what's asked of you won't get very far -- in life or in your job search. Applying to jobs with the same CV and the same cover letter (or none at all) is pure laziness. And, if you won't spend extra time on yourself and your application materials, you probably won't do it for a client either.
Red flag No. 10: You lack objective or ambition
If you have no long-term goals, then you really have no short-term goals either. Long-term goals may change, however you need to have some concept of where you want to go. Know where you want to go and how you plan to get there. Otherwise you seem unfocused and unmotivated, which are two big no-no's for an applicant.
We are specialists in Medical & Pharmaceutical Recruitment, to secure your next role in this sector call us at 20:20 Selection Ltd on 0845 026 2020 and speak to one of our consultants or visit www.2020selection.co.uk to view our current Medical Sales vacancies
(Adapted from CareerBuilder)
It's a hard concept that most job seekers have trouble wrapping their heads around, but applicants frequently -- inadvertently -- raise red flags to recruiting managers that immediately scream, "Don't employ me!" You might not be raising them on purpose, but there are ways to avoid them.
Not sure if you're unknowingly blowing your chances at securing your dream position? Here are 10 red flags to be wary of during your next job hunt:
Red flag No. 1: Your CV is lacking any specific achievements that distinguish you from other Medical Representatives
When you're crafting your CV, you should focus on highlighting relevant skills and accomplishments that are in line with the position for which you are applying. Highlighting your sales successes is key!
Red flag No. 2: You have long gaps between jobs on your CV
Even if your long departure from the work force is valid, extended lapses of unemployment might say to an employer, "Why weren't you wanted by anyone?" Anytime you have more than a three-month gap of idleness on your CV, legitimate or otherwise, be prepared to explain yourself.
Red flag No. 3: You aren't prepared for the interview
There are many ways to be unprepared for an interview: You haven't researched the company, you haven’t researched the products & therapy area, you don't have any questions prepared, etc. Plain and simple, do your homework before an interview. Explore the company online, prepare answers to Competency Based questions and have someone give you a mock interview. The more prepared you are, the more employers will take you seriously.
Red flag No. 4: You didn't provide any evidence of success
In today’s competitive market use of evidence/brag file can be the difference between progressing to the next stage and being told that there ‘where stronger people on the day.’ You need to prove how successful you have been (the more specific you can be the better) and differentiate yourself from other candidates. Do not wait to be asked for your evidence, use it as a sales aid to illustrate your answers. YOU are your product!
Red flag No. 5: You only have negative things to say about previous employment
If you feel aggrieved or down-beat about your current/prior employer, it could be very tempting to want to tell anyone who will listen how much of ‘bad time’ you have experienced-- but a recruiting manager for a coveted job is not that person. There are hundreds of ways to turn negative things about an old job into positives. Thought your last job was a dead end? Spin it by saying, "I felt I had gone as far as I could go in that position. I'm looking for something with more opportunity for advancement."
Red flag No. 6: You've held seven different jobs -- in the past six years
Job hopping is a new trend in the working world. Workers are no longer staying in a job for 10-20 years; they stay for a couple and move on to the next one. While such a tactic can further your career, switching jobs too often will raise a prospective employer's antenna. Too many jobs in too little time tells employers that either you can't hold a job or you have no loyalty. Be prepared to explain your reasoning/rationale
Red flag No. 7: You give inconsistent answers in your interview
One tactic recruiting manager’s use during the recruitment process is to ask you the same question in several different ways. This is mostly to ensure that you're genuine with your answers and not just telling an employer what he or she wants to hear. Keep your responses sincere throughout the entire process and you should be good to go.
Red flag No. 8: You lack flexibility
Most people know what they want in a job as far as benefits, basic salary, bonus, etc. If you're unable to be flexible with some of your (unrealistic?) expectations, however, you're going to have a difficult time finding a job. Have a bottom line in terms of what you want before you start the job hunting process and be willing to bend a bit if necessary.
Red flag No. 9: Your application was -- in a word – lazy
Only doing the bare minimum of what's asked of you won't get very far -- in life or in your job search. Applying to jobs with the same CV and the same cover letter (or none at all) is pure laziness. And, if you won't spend extra time on yourself and your application materials, you probably won't do it for a client either.
Red flag No. 10: You lack objective or ambition
If you have no long-term goals, then you really have no short-term goals either. Long-term goals may change, however you need to have some concept of where you want to go. Know where you want to go and how you plan to get there. Otherwise you seem unfocused and unmotivated, which are two big no-no's for an applicant.
We are specialists in Medical & Pharmaceutical Recruitment, to secure your next role in this sector call us at 20:20 Selection Ltd on 0845 026 2020 and speak to one of our consultants or visit www.2020selection.co.uk to view our current Medical Sales vacancies
(Adapted from CareerBuilder)
Subscribe to:
Posts (Atom)
